• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    11/25/22 12:31:55 PM ET
    $BPTS
    $CGTX
    $COSM
    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BPTS alert in real time by email

    Gainers

    • Peak Bio (NASDAQ:PKBO) stock moved upwards by 34.1% to $6.37 during Friday's regular session. Peak Bio's stock is trading at a volume of 493.5K shares as of 12:30 EST. This is 36.6% of its average full-day volume over the last 100 days. The company's market cap stands at $127.7 million.
    • Cosmos Holdings (NASDAQ:COSM) shares increased by 30.09% to $0.42. As of 12:30 EST, Cosmos Holdings's stock is trading at a volume of 137.1 million, which is 517.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $34.8 million.
    • Cognition Therapeutics (NASDAQ:CGTX) shares increased by 21.76% to $2.35. Trading volume for this security as of 12:30 EST is 1.2 million, which is 1303.9% of its average full-day volume over the last 100 days. The company's market cap stands at $68.0 million.
    • Vapotherm (NYSE:VAPO) shares moved upwards by 20.37% to $0.68. Trading volume for Vapotherm's stock is 169.4K as of 12:30 EST. This is 77.3% of its average full-day volume over the last 100 days. The company's market cap stands at $18.1 million.
    • Nutex Health (NASDAQ:NUTX) shares moved upwards by 16.34% to $1.21. As of 12:30 EST, Nutex Health's stock is trading at a volume of 5.0 million, which is 152.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $786.2 million. The company's, Q3 earnings came out 4 days ago.
    • Statera BioPharma (NASDAQ:STAB) stock rose 14.32% to $0.12. Trading volume for Statera BioPharma's stock is 2.5 million as of 12:30 EST. This is 85.0% of its average full-day volume over the last 100 days. The company's market cap stands at $6.4 million.

    Losers

    • Venus Concept (NASDAQ:VERO) shares decreased by 16.5% to $0.29 during Friday's regular session. As of 12:30 EST, Venus Concept's stock is trading at a volume of 1.3 million, which is 152.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $19.7 million.
    • OncoSec Medical (NASDAQ:ONCS) shares decreased by 13.01% to $3.25. OncoSec Medical's stock is trading at a volume of 226.1K shares as of 12:30 EST. This is 78.1% of its average full-day volume over the last 100 days. The company's market cap stands at $5.8 million.
    • Puma Biotechnology (NASDAQ:PBYI) stock decreased by 12.98% to $4.12. Trading volume for Puma Biotechnology's stock is 332.6K as of 12:30 EST. This is 147.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $187.8 million.
    • NeuroOne Medical Tech (NASDAQ:NMTC) shares fell 12.52% to $1.53. As of 12:30 EST, NeuroOne Medical Tech's stock is trading at a volume of 545.9K, which is 231.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $24.8 million.
    • Biophytis (NASDAQ:BPTS) stock declined by 10.56% to $0.38. The market value of their outstanding shares is at $7.8 million.
    • Landos Biopharma (NASDAQ:LABP) stock declined by 9.55% to $0.22. The current volume of 122.0K shares is 45.3% of Landos Biopharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $8.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BPTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BPTS
    $CGTX
    $COSM
    $LABP

    CompanyDatePrice TargetRatingAnalyst
    NeuroOne Medical Technologies Corporation
    $NMTC
    5/5/2025$1.45Buy
    Ladenburg Thalmann
    Cognition Therapeutics Inc.
    $CGTX
    12/19/2024$1.00 → $1.50Neutral → Buy
    B. Riley Securities
    Nutex Health Inc.
    $NUTX
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    Nutex Health Inc.
    $NUTX
    9/18/2024$45.00Buy
    Maxim Group
    Cognition Therapeutics Inc.
    $CGTX
    7/30/2024Overweight → Neutral
    Cantor Fitzgerald
    Nutex Health Inc.
    $NUTX
    2/22/2023$3.00Outperform
    Northland Capital
    Vapotherm Inc.
    $VAPO
    5/6/2022$12.00 → $5.00Buy → Hold
    Canaccord Genuity
    Landos Biopharma Inc.
    $LABP
    4/12/2022$30.00 → $1.40Buy → Hold
    Jefferies
    More analyst ratings

    $BPTS
    $CGTX
    $COSM
    $LABP
    SEC Filings

    View All

    SEC Form 10-K filed by Puma Biotechnology Inc

    10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

    2/26/26 4:41:18 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

    2/26/26 4:16:40 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Other Events

    8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

    2/25/26 4:30:28 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $BPTS
    $CGTX
    $COSM
    $LABP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 million in 2024. Based on accounting principles generally accepted in the United State

    2/26/26 4:05:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $BPTS
    $CGTX
    $COSM
    $LABP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Numerical Tech with a new price target

    Ladenburg Thalmann initiated coverage of Numerical Tech with a rating of Buy and set a new price target of $1.45

    5/5/25 8:32:14 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Cognition Therapeutics upgraded by B. Riley Securities with a new price target

    B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously

    12/19/24 7:33:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maxim Group reiterated coverage on Nutex Health with a new price target

    Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously

    11/12/24 8:15:57 AM ET
    $NUTX
    Real Estate

    $BPTS
    $CGTX
    $COSM
    $LABP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $BPTS
    $CGTX
    $COSM
    $LABP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Auerbach Alan H was granted 159,778 shares, increasing direct ownership by 2% to 7,305,729 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    2/20/26 8:29:13 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Hunt Douglas M was granted 49,394 shares, increasing direct ownership by 32% to 205,301 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    2/20/26 8:28:40 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Nougues Maximo F was granted 46,739 shares, increasing direct ownership by 24% to 240,023 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    2/20/26 8:28:04 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTS
    $CGTX
    $COSM
    $LABP
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF WESLEY BAMBURG AS ITS NEW CHIEF OPERATING OFFICER

    HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments  in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Wesley Bamburg as the Company's Chief Operating Officer, effective October 13, 2025. Mr. Bamburg is an accomplished healthcare executive with 20 years of Fortune 500 experience in healthcare operations, business development, integrated network management, and physician relations. Mr. Bamburg has served as Chief Operating Officer for HCA Houst

    9/22/25 6:30:00 AM ET
    $NUTX
    Real Estate

    NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

    EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, "We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business.

    6/3/25 8:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $BPTS
    $CGTX
    $COSM
    $LABP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/14/24 3:41:01 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $BPTS
    $CGTX
    $COSM
    $LABP
    Financials

    Live finance-specific insights

    View All

    Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 million in 2024. Based on accounting principles generally accepted in the United State

    2/26/26 4:05:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutic

    2/23/26 4:15:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care